Company

Xlife Sciences AG

Headquarters: Zürich, Switzerland

Employees: 6

CEO: Dr. Christoph Antz

FSX: XLS -2.31%

Market Cap

€206.3 Million

EUR as of Feb. 1, 2022

US$233.3 Million

Market Cap History

Xlife Sciences AG market capitalization over time

Evolution of Xlife Sciences AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Xlife Sciences AG

Detailed Description

Xlife Sciences AG focuses on the development of life sciences technologies. The company's projects and pipeline include biotech/therapies and technology platforms for antibody therapy, including obesity, acute myeloid leukemia, and acute lymphocytic leukemia; nanovesikel therapy comprising arthritis, MS, and ALS; painkiller solution; screening technology of antibodies; and modification of antibodies and breakdown of polygeny (genetics). Its projects and pipeline also include medical technology and artificial intelligence comprising 3D bioprinting for life; medical technology comprising reprocessing of instruments of surgical robots; medical devices for the early detection of dementia and Parkinson's disease; development of bile duct implants; and analysis software (AI) for the diagnosis/evaluation of X-ray and MRI images for early detection of prostate cancer. The company is headquartered in Zurich, Switzerland.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Xlife Sciences AG has the following listings and related stock indices.


Stock: FSX: XLS wb_incandescent

Stock: Munich: XLS wb_incandescent

Stock: XETR: XLS wb_incandescent

Details

Headquarters:

Klausstrasse 19

Zürich, 8008

Switzerland